Stage Iii Non Small Cell Lung Cancer clinical trials

Explore recruiting stage iii non small cell lung cancer clinical trials.

Recruiting stage iii non small cell lung cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Stage Iii Non Small Cell Lung Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

IFCT-2501 IDEATION ctDNA-guIDEd consolidATION immunotherapy after chemoradiotherapy in patients with stage III non-small cell lung cancer

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Prospective Phase-II Trial of induction chemotherapy and chemoradiotherapy plus/minus the PD-L1 antibody durvalumab followed by surgery or definitive chemoradiation boost and consolidation durvalumab in resectable stage III NSCLC (ESPADURVA)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

ChemoRadiotherapy with Or Without surgery followed by consolidation Durvalumab (CROWD): a phase IV feasibility trial

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

A Phase II, Single-Arm Study of Atezolizumab in Patients with Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer who have not Progressed after Platinum-Based Concurrent Chemoradiation

Slovenia, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A multicenter randomized open label phase II study evaluating the efficacy and the tolerance of adding cemiplimab to Sequential hyPOfractionated chemoRADiotherapy in unfit or elderly patients with unresectable stage III non-small cell lung cancer

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared with Durvalumab in Patients with Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer who have not Progressed after Concurrent Platinum-Based Chemoradiation (SKYSCRAPER-03)

Poland, Spain, Portugal, Belgium, France, Greece +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Stage Iii Non Small Cell Lung Cancer trials by city

Stage Iii Non Small Cell Lung Cancer in Toronto Stage Iii Non Small Cell Lung Cancer in Vancouver Stage Iii Non Small Cell Lung Cancer in Montreal Stage Iii Non Small Cell Lung Cancer in Calgary Stage Iii Non Small Cell Lung Cancer in Edmonton Stage Iii Non Small Cell Lung Cancer in Ottawa Stage Iii Non Small Cell Lung Cancer in Winnipeg Stage Iii Non Small Cell Lung Cancer in Quebec City Stage Iii Non Small Cell Lung Cancer in Hamilton Stage Iii Non Small Cell Lung Cancer in Kitchener Stage Iii Non Small Cell Lung Cancer in London Stage Iii Non Small Cell Lung Cancer in Halifax Stage Iii Non Small Cell Lung Cancer in New York Stage Iii Non Small Cell Lung Cancer in Los Angeles Stage Iii Non Small Cell Lung Cancer in Chicago Stage Iii Non Small Cell Lung Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease